Track Hologic, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Hologic, Inc. HOLX · Stock Open Hologic, Inc. in new tab

76.01 USD
P/E
31.54
EPS
2.41
P/B
3.23
ROE
10.86
Beta
0.70
Target Price
76.67 USD
Loading chart...
Key Metrics
P/E31.54
EPS2.41
Book Value23.51
Price to Book3.23
Debt/Equity48.05
% Insiders0.836%
Growth
Revenue Growth0.03%
Earnings Growth-0.09%
Estimates
Forward P/E15.66
Forward EPS4.86
Target Mean Price76.67

DCF valuation

Model fair value for Hologic, Inc. (HOLX)
Result
Sign in to run the valuation for HOLX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 76.67 USD (low 76.00, high 78.00)
Low 76.00
Mean 76.67
High 78.00
Price 76.01
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Hologic, Inc. Logo Hologic, Inc. Analysis (HOLX)

United States Health Care Official Website Stock

Is Hologic, Inc. a good investment? Hologic, Inc. (HOLX) is currently trading at 76.01 USD. Market analysts have a consensus price target of 76.67 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 31.54. This high multiple suggests investors have priced in significant future growth expectations.

Investor FAQ

Does Hologic, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Hologic, Inc.?

Hologic, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Exchange Ticker
NMS (United States) HOLX
LSE (United Kingdom) 0J5Q.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 26, 1996 2:1
Dec. 1, 2005 2:1
April 3, 2008 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion